Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Recruiting

• Conditions: Cerebral Infarction; Myocardial Infarction

• Registration Number: NCT01372800
• Lead Sponsor: Xijing Hospital

Brief Summary

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Detailed Description

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Study Timeline

• Study Start: 2011-05-01
• Study First Submitted: 2011-06-10
• Study First Submitted QC: 2011-06-11
• Study First Posted: 2011-06-14
• Status Verified: 2025-01
• Last Update Submitted: 2025-02-04
• Last Update Posted: 2025-02-07
• Primary Completion: 2026-10-01
• Study Completion: 2036-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30000

Inclusion Criteria

• available for 5 years of follow-up study

Exclusion Criteria

• Death caused other than cardiovascular and cerebralvascular diseases till the study ends
• Floating Population
• Pregnancy, lactation, or child bearing women
• Tumor
• Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
• Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
• Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Participants with major adverse events	5 years	Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.

Secondary Outcome Measures

Name	Time	Method
serum adiponectin concentration, activity and isoforms	5 years	serum adiponectin concentration, activity and isoforms will be monitored once per year.
blood routine, glucose and lipid profile; ECG;	5 years	the tests mentioned above will be taken once per year

Trial Locations

Locations (1)

Xijing Hospital; 🇨🇳 Xi'an, Shaanxi, China